Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06572514
Status:
RECRUITING
Last Update Posted:
None
First Post:
2023-12-17
Brief Title:
De-escalation Radiation Strategy After NAC in Combination With ICI in LAHNSCC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Exploratory Study of the Feasibility of De-escalating Radiation Strategy After NAC in Combination With Immunotherapy in LAHNSCC
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a single-arm exploratory study conducted in LAHNSCC Eligible patients received two cycles of pembrolizumab immunotherapy in combination with albumin-bound paclitaxel and cisplatin induction chemotherapy followed by definitive concurrent radiochemotherapy Three months after the completion of radiotherapy a follow-up examination was conducted and salvage surgery or systemic therapy was performed as necessary based on the follow-up results
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None